Enanta Pharma (NASDAQ: ENTA) reported Q2 EPS of ($1.53), $0.14 worse than the analyst estimate of ($1.39). Revenue for the quarter came in at $19.5 million versus the consensus estimate of $20.65 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.